{"entity":{"id":"chek2","kind":"target","name":"CHEK2","aka":["checkpoint kinase 2","Serine/threonine-protein kinase Chk2","CDS1","CHK2","HuCds1","PP1425","bA444G7","RAD53"],"tldr":"CHEK2 (Serine/threonine-protein kinase Chk2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Sarcomas and 5 more.","summary":"Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T].\n\nCIViC holds 9 clinical evidence items and 0 assertions across 6 variants, naming Olaparib, Enzalutamide and Talazoparib. Open Targets scores its association with cancer at 0.91 (direct and indirect evidence; datatypes genetic literature 0.86, clinical 0.19, affected pathway 0.76, literature 0.99, genetic association 0.95, somatic mutation 0.88). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Invasive Breast Carcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:16627","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627"},{"label":"UniProt O96017","url":"https://www.uniprot.org/uniprotkb/O96017/entry"},{"label":"NCBI Gene 11200","url":"https://www.ncbi.nlm.nih.gov/gene/11200"},{"label":"Ensembl ENSG00000183765","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183765"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets","intogen"],"cancers":["breast-cancer","prostate","sarcoma","colorectal","ovarian","lung-cancer","thyroid","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["homologous-recombination-repair"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.19; IntOGen calls it an activating (Act) driver in 1 cohort; CIViC holds 9 clinical evidence items on its variants; UniProt keyword \"DNA repair\". Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CHEK2","role":["drug-target","oncogene-driver","biomarker","dna-repair"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:16627","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O96017","url":"https://www.uniprot.org/uniprotkb/O96017/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CHEK2","url":"https://civicdb.org/features/8950","note":"9 evidence items, 0 assertions, 6 variants; diseases: Prostate Cancer, Cancer, Castration-resistant Prostate Carcinoma, Breast Cancer (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000183765","url":"https://platform.opentargets.org/target/ENSG00000183765/associations","note":"association with cancer (MONDO_0004992) 0.91; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.58, colorectal cancer 0.74, gastric cancer 0.63, prostate cancer 0.80, ovarian cancer 0.73, endometrial cancer 0.54 (GraphQL API, CC0)"},{"label":"IntOGen CHEK2","url":"https://www.intogen.org/search?gene=CHEK2","note":"driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:16627","ensembl":"ENSG00000183765","uniprot":"O96017","entrez":"11200","biology":"Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Location: Nucleus; Nucleus, PML body; Nucleus, nucleoplasm (UniProt). Locus 22q12.1 (HGNC).","whereFound":["Breast cancer: Open Targets association 0.87 with breast cancer (MONDO_0007254); CIViC evidence names this disease","Prostate cancer: Open Targets association 0.80 with prostate cancer (MONDO_0008315); CIViC evidence names this disease","Sarcomas: Open Targets association 0.75 with sarcoma (MONDO_0005089)","Colorectal cancer: Open Targets association 0.74 with colorectal cancer (MONDO_0005575)","Ovarian cancer: Open Targets association 0.73 with ovarian cancer (MONDO_0008170)","Lung cancer: Open Targets association 0.69 with lung cancer (MONDO_0008903)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/chek2/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"pathway":[{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/"}]}}